PCR Journal Club

This trial found that, in ACS patients undergoing PCI, DP-DES and BP-DES had similar patient-oriented outcomes at three years, but BP-DES had higher device-oriented composite outcomes, mainly due to increased TLR risk.

The results of this study show that IVUS guidance is associated with less late lumen loss compared to angiography guidance in HBR patients undergoing DCB angioplasty.

The optimal duration of short DAPT in ACS patients is unknown, therefore this analysis of the XIENCE Short DAPT programme compared the clinical outcomes of one versus three months DAPT in HBR patients with and without ACS.

This sub-analysis denotes that medically treated diabetic patients with FFR-negative, TCFA-carrying target lesions were associated with a higher rate event rate compared to angiographically similar ischemic target lesions that underwent revascularization.

The OCTIVUS trial was a prospective multicentre, open-label, randomised controlled trial comparing OCT guided PCI with IVUS guided PCI. In this pre-specified sub-study, the authors report the outcomes in patients with complex coronary lesions undergoing OCT- or IVUS-guided PCI. 

The STOPDAPT-2 trial was a multicenter, open-label, adjudicator-blinded, randomised control trial comparing clopidogrel monotherapy after one-month DAPT with aspirin monotherapy following 12-months DAPT in patients undergoing PCI with a everolimus-eluting stent...

This is a trial aiming to assess QFR and 3D-QCA DS% of all the non-infarct related arteries (IRA) with 3D-QCA DS% in all patients presenting with STEMI/NSTEMI and undergoing coronary angiography. 

This patient-level analysis of randomized trials comparing PCI vs CABG for the treatment of low-to-intermediate CAD involving the LM confirms the absence of long-term differences in mortality between revascularization techniques, regardless of the clinical presentation.

While the choice between PCI and CABG for LMCA disease continues to be one of the most controversial topics, patient characteristics & comorbidities must be taken into account, as must the external validity of the results of RCTs in the real world, as the SWEDEHEART registry does.

The aim of the current trial was to explore if direct P2Y12 inhibitor monotherapy was feasible and safe in patients with NSTEMI undergoing PCI.